A Combination of Atractylon and Magnolol Inhibits the Survival of Hepatocellular Carcinoma Cells through Promoting
Haojia Wu1, Jing Bi1, Qinglong Guo1
1National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen 518112, China.
Background:
New medications and treatment approaches are needed due to the rising frequency of hepatocellular carcinoma; pharmacological combination therapy is one such approach that is being thoroughly studied.
Methods:
After co-treatment with atractylon and magnolol, cell viability and death were assessed using a CCK8 kit and an LDH kit, cell migration and invasion were assessed using a transwell assay, and related proteins were detected by western blotting after applying specific drug treatments or disturbances.
Results:
In both HepG2 and Hep3B cells, magnolol and atractylon demonstrated significant synergistic effects, including the inhibition of cell proliferation, migration, and invasion. This mechanism may be mediated by the mTOR/TFEB signaling pathway.
Discussion:
Based on our experimental findings and the existing literature, the combined application of atractylon and magnolol is considered to have promising therapeutic potential for suppressing the growth of hepatocellular carcinoma cells. This warrants further investigation to elucidate the underlying mechanisms and optimize this combinatorial approach.
Conclusion:
The synergistic effect of magnolol and atractylon was found to be superior to that of either compound alone, particularly in terms of cell viability, migration, and invasion. The use of both drugs leads to autophagy-associated cell death, and the mTOR/TFEB signal pathway is an important factor in this process.
Insights
The combination of atractylon and magnolol shows significant synergistic effects in suppressing hepatocellular carcinoma cell growth, migration, and invasion. This approach offers promising therapeutic potential for cancer treatment.
Area of Science:
- Hepatocellular Carcinoma Research
- Pharmacological Combination Therapy
- Cancer Cell Biology
Background:
- Hepatocellular carcinoma (HCC) incidence is rising, necessitating novel therapeutic strategies.
- Pharmacological combination therapy is an actively researched approach for HCC treatment.
Purpose of the Study:
- To investigate the synergistic effects of atractylon and magnolol in HCC.
- To explore the underlying mechanisms of this combination therapy.
Main Methods:
- Cell viability and death assessed using CCK8 and LDH kits.
- Cell migration and invasion evaluated via Transwell assays.
- Protein expression analyzed by Western blotting.
Main Results:
- Atractylon and magnolol exhibited significant synergistic effects in HepG2 and Hep3B cells.
- Combined treatment inhibited cell proliferation, migration, and invasion.
- The mTOR/TFEB signaling pathway was identified as a key mediator.
Conclusions:
- Combined atractylon and magnolol show therapeutic potential against HCC.
- The synergistic effect enhances autophagy-associated cell death.
- Further research is warranted to optimize this combination therapy.
Related Concept Videos
01:18Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...